In this conference update video, Prof. Shaheenah Dawood joins us from ASCO 2024 to share her insights into new key breast cancer trial data from the DESTINY-Breast06, postMONARCH and INAVO120 trials and the potential impact on clinical practice.

 

ASCO 2024 selected breast cancer abstracts

  • Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: Primary results from DESTINY-Breast06 (DB-06).
    Curigliano G, et al.
    Abstract LBA1000, ASCO 2024
  • Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
    Kalinsky K, et al.
    Abstract LBA1001, ASCO 2024
  • First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: INAVO120 Phase 3 randomized trial additional analyses.
    Juric D, et al.
    Abstract #1003, ASCO 2024

 

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Watch the video now
Other episodes in this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Current Episode
ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024

Share this programme
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

animated-video Animated Video
Oncology 
Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
podcast Podcast

Episode

2

of 2

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Dr Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery Global Liver Institute
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
Testing to treatment of BRAF-mutant metastatic NSCLC

Medical experts share their insights on testing and treatment

Experts
Prof. David Planchard, Dr Federico Cappuzzo
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. This content is intended for HCPs outside the UK & ROI only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
HCC podcast series part 1: The use of IO in unresectable HCC

Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice

Experts
Dr Rachna Shroff, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.